Indalo Therapeutics’ lead investigational anti-fibrotic candidate, IDL-2965, is safe and shows favorable pharmacokinetics (absorption, distribution, and elimination in…
Articles by Marta Figueiredo, PhD
Different combinations of medications to manage comorbidities (additional conditions) may influence disease progression in people with idiopathic pulmonary fibrosis…
People with idiopathic pulmonary fibrosis (IPF) and right heart dysfunction may benefit more from a therapy combining Ofev (nintedanib) with …
A plant compound called parthenolide significantly reduces lung fibrosis and its associated inflammatory responses, according to a study conducted in…
Gossypol — a pharmacological inhibitor of the LDHA enzyme — shows promising results in the prevention and treatment of lung…
Chest pain may be a neglected symptom of idiopathic pulmonary fibrosis (IPF), finds a Finnish study that also suggests using…
A real-world study in Britain confirms that Ofev (nintedanib) is a safe and effective treatment for idiopathic pulmonary…
The National Heart, Lung, and Blood Institute of the National Institutes of Health (NIH) recently awarded a team of researchers at …